Revitalize Your Health and Fitness

Semaglutide, sold under the brand names Ozempic (FDA Approved 2017), Wegovy (FDA Approved 2021), & Rybelsus (FDA Approved 2019)

Losing weight can be an incredibly difficult endeavor which can impact your lifestyle. We all know there are no magic pills & nothing works better than time & effort. Semaglutide can assist with weight loss, fat loss, & even helps control insulin levels. 

The best part, Semaglutide only has to be administered once a week.

Semaglutide, often referred to by the brand names Ozempic and Wegovy, is a Glucagon-like peptide-1 (GLP-1) produced by the gut. It increases insulin production, a hormone that lowers the blood sugar level while inhibiting glucagon secretion, which is a hormone that raises blood sugar, reduces appetite and energy intake while delaying gastric emptying. 

In 2017 this drug was approved as an anti-diabetic medication used to treat type 2 diabetes and obesity. In June 2021, it got approved for chronic weight management in obese individuals with a (BMI) ≥ 30 kg/m2) or overweight (initial BMI ≥ 27 kg/m2) with at least one weight-related comorbidity.

Retatrutide is a peptide hormone that activates three naturally occurring receptor agonists in our bodies:

• Glucagon-like peptide (GLP-1)
• Glucose-dependent insulinotropic polypeptide (GIP)
• Glucagon receptors

Due to this triple receptor agonist activation, retatrutide has received the nickname Triple G.  In the medical community this is called triagonist.  The triple hormone effect is unprecedented in the weight loss industry.

The latest clinical trial results showed that Retatrutide has the ability to help people lose 24.2% of their body weight in only 48 weeks.

Works similarly to Ozempic (Semaglutide) or Mounjaro (Tirzepatide).

The 3 mentioned hormones work to control blood sugar levels.

• GLP-1
• GIP
• Glucagon

Cagrilintide is a long-acting analogue of a hormone our own body makes, called amylin.  Amylin is made by our pancreas, secreted in response to eating.  Amylin talks to our brain to tell us that we feel full and is also believed to act on parts of the brain involved in the wanting and liking of food (the ‘hedonic’ area), thus having a potential impact on emotional eating and food preferences.  It slows down the stomach in response to food intake and also suppresses glucagon after meals.  

Cagrilintide is 84% identical to the amylin our own body produces, having been modified to last longer, allowing treatment to be once weekly. It is important that cagrilintide acts not only to induce satiety, but also seems to regulate hedonic (emotional/wanting/liking) aspects of food intake. 

 Many people with elevated weight struggle with cravings and the irresistible pleasure of food and describe a relief from these draws when on medication that dampens these feelings.

Benefits of Cagrilintide Peptide Therapy Over Time

•   Reduces food intake by reducing appetite
•   Slows food digestion in the stomach
•   Decrease in overall bodyweight
•   Decreased cardiovascular outcomes in subjects with type 2 diabetes
•   Lower HbA1c levels
•   Lowers blood sugar by increasing insulin and lowering glucagon.
•   Improves Fatty Liver Disease – reduces fatty acids in the liver.
•   Improves metabolism

Survodutide (BI 456906) is a novel, dual agonist of the glucagon and GLP-1 receptors that is administered once weekly via a subcutaneous injection.

Results from a phase 2 clinical trial of survodutide (also known as BI 456906), a novel dual glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R) agonist, showed up to 18.7% weight loss in overweight or obese individuals through a 46-week time frame.

The randomized, double-blind, placebo-controlled, dose-finding trial, enrolled 387 participants with a body mass index (BMI) of 27 kg/m2 or higher, who were randomly assigned to receive weekly subcutaneous injections of survodutide at varying doses (0.6 mg, 2.4 mg, 3.6 mg, or 4.8 mg) In a recent phase 2 dose-finding trial, treatment with survodutide resulted in up to a mean 14.9% weight loss over 46 weeks in patients with a body mass index (BMI) ≥27 kg/m2 and without diabetes.

By activating both the glucagon and GLP-1 receptors, survodutide may inhibit both appetite and improve energy expenditure. The findings not only show significant weight loss with increasing doses of survodutide, but we also saw a favorable safety profile

Those treated with survodutide experienced significantly greater body weight loss than semaglutide after 16 weeks of treatment: up to −8.7% mean body weight loss with ≥1.8 mg of survodutide weekly vs −5.3% with semaglutide 1.0 mg weekly.

OXM3 (also known as mazdutide) is a GLP-1R and GCGR dual agonist. As a mammalian oxyntomodulin (OXM) analogue, with the effects of GLP-1 receptor agonists to promote insulin secretion, lowering blood glucose and reducing body weight, mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor. 

Mazdutide has demonstrated robust weight loss and glucose-lowering effects in clinical studies as well as improvements in multiple cardio-metabolic indicators including reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, liver fat content and improved insulin sensitivity. Mazdutide is a dual glucagon-like peptide 1 receptor agonist (GLP-1RA) and glucagon receptor agonist, the first in its class. By activating both GLP1R and glucagon receptors it helps regulate appetite, metabolism, and improve glucose control. This dual effect appears promising but more clinical trials are needed.

GLP-1 receptors are widely distributed on the beta-cells of the pancreas, brain, and other tissues and are involved in the control of blood sugar levels by enhancing insulin secretion, among other effects. GLP-1 receptor agonists (GLP-1RAs) are already widely used in the treatment of type 2 diabetes because they stimulate insulin synthesis and secretion in a glucose-dependent manner and cause weight loss. They also delay gastric emptying, regulate blood lipid metabolism, reduce fat deposition, and are neuroprotective, anti-infectious, and cardiovascular protective.

Glucagon receptor agonists on their own are not a good therapeutic option because they increase the liver's production of glucose, but if they are combined with GLP-1RAs then they are effective at reducing fat mass and improving glucose tolerance.

MOTS-c is a mitochondrial-derived peptide and what is called an exercise mimetic. Considering that mitochondria are one of the most important organelles in our cells, it is not surprising that the benefits are vast with this peptide. MOTS-c activates at the cellular and systemic level, and the benefits are exceptionally far-reaching. They include implications in the regulation of longevity, obesity, diabetes, and physical performance. 

MOTS-c can translocate into the nucleus in response to metabolic stress and regulation of adaptive nuclear gene expression. This allows the peptide to promote resistance to metabolic stress by upregulating the mitochondrial genome. 

Multiple studies have demonstrated MOTSc’s ability to enhance lipid beta-oxidation, increase thermogenic brown fat, decrease fat gain on a high-fat diet, and improve glucose uptake during glycolysis. 

MOTS-c can be used for the benefit of weight loss, improving insulin sensitivity, energy production, neuro-protection, and longevity. Given, Mots-C improves intracellular NAD+ and AMPk, which are associated with metabolism and longevity, it’s an exciting multi-purpose peptide for those seeking optimization.

Tesamorelin is a growth hormone-releasing hormone analog that has been shown to increase IGF-1 levels and decrease adipose tissue. It can also reduce c-reactive proteins which are created in the liver in response to inflammation and inversely associated with general biomarkers of health. Although the main focus is on weight loss, Tesamorelin can improve the cognitive function in healthy adults with an increased risk of Alzheimer’s disease.   A controlled study of 152 adults who self-administered subcutaneous injections of Tesamorelin or a placebo for 20 days, showed extremely favorable effects on their cognitive state despite their disease state. 

Tesamorelin has been used actively under the brand name Egrifta for a decade for a specific subset of the population with disease complications that include excess abdominal fat.  It can be useful in reducing visceral adiposity, positively affecting insulin resistance, and lowering triglyceride levels in healthy people. Additionally, the benefits demonstrated the reduction in visceral abdominal fat that remained for upwards of 52 weeks according to a double-blind placebo clinical trial. 

Tesamorelin also improves the overall framework of the body. This peptide works well for individuals 30+ since the production of GH naturally begins to lower as we age, and it helps improve it. Physical activity supports the release of GH as well. 

This peptide is the mildest growth hormone-releasing peptide and also the most versatile one. It is said to be the most suitable peptide as it doesn’t induce these side effects like desensitization, hunger stimulation, or unnecessary plasma growth, like other peptides.

AOD-9604 is a breakthrough peptide that has shown great results without many of the side effects or risks of other more commonly prescribed fat loss medications. 

It works by mimicking the way natural Growth Hormone regulates fat metabolism but without the adverse effects on blood sugar or growth that is seen with unmodified Growth Hormone. Like Growth Hormone, it stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis (the transformation of nonfat food materials into body fat). It also processes many other regenerative properties associated with growth hormone.

AOD-9604 can provide patients with various metabolic benefits, including:

• Cartilage repair
• Metabolism regulation
• Enhanced muscle growth
• Insulin and blood sugar management
• Reduced body fat

Patients using AOD-9604 have also been found to lose five times the amount of body fat compared to the average person. 

Aside from the weight loss, AOD-9604 can also help patients maintain a healthier blood glucose level than some healthy adults without the peptide. 

CJC 1295 with DAC (aka Drug Affinity Complex) is known as a long-acting GHRH (growth hormone stimulating hormone). However, regardless. of whether CJC 1295 is the DAC version or not its primary purpose is to boost protein synthesis levels and help fuel the growth of muscle tissue in the body.

Some claim CJC 1295 with DAC has an advantage over CJC 1295 (without DAC) given it does not have a limited duration of action. However, others believe we should be concerned about unregulated and inconsistent HGH release associated with DAC’s extended release. 

A study of healthy participants between the ages of 21 and 61 found that CJC 1295 with DAC prolonged elevated levels of growth hormone as well as IGF-1 with no increase in prolactin, leading to fat loss and increased muscle mass via improved protein synthesis.  

CJC 1295 DAC can be used for relatively short periods since it lengthens the duration of the body’s natural HGH secretion. However, your dose timing doesn’t impact your body’s decision when those natural GH peaks occur, which isn’t exactly advantageous. So, for example, if your blood sugar is high during one of those HGH peaks, then HGH will not convert to IGF-1, and you will lose the benefits. 

CJC 1295 stimulates growth hormone secretion and will keep a steady increase of HGH and IGF-1, leading to fat loss and muscle growth. With no increase in prolactin and better stimulation and release of HGH, clinical results showcase fat loss, increased lean muscle mass, and better lipid profiles. Another benefit of this peptide is its ability to promote slow-wave sleep (e.g. Delta sleep), which is the sleep stage associated with muscle recovery and memory formation. 

Ipamorelin is a growth hormone secretagogue, which aids the body’s production of endogenous growth hormone. 

Benefits include:

• Accelerated fat loss
• Improved sleep
• Long-term growth hormone production
• Promote lean muscle growth
• Improve skin condition
• Boost metabolism
• Increase energy level
• Slows osteoporosis
• Increase in libido
• Improved mood

Combining Ipamorelin with CJC 1295 prolongs the boost of HGH production, allowing longer-term benefits. 

Ipamorelin does this by stimulating the pituitary gland to release growth hormone naturally by its action as an analog to the well-known hunger hormone ghrelin. 

Unlike a lot of other GHRP’s, however, Ipamorelin does not have a laundry list of negative side effects like elevated cortisol or increased appetite, which allows patients to use it for a broad range of issues and goals. Many patients use Ipamorelin for a short amount of time (~3 months) for fat loss benefits, increased metabolism, and general improvements in their body composition. 

Growth hormone production decreases by about 15% with each decade of life, resulting in decreased mental and physical function. 

Ipamorelin may offer several hormonal regulation benefits within the realm of women’s health. GH can aid in mood stabilization, so utilizing Ipamorelin to support GH release may help regulate emotional fluctuations that can occur with hormonal changes.

Estrogen stimulates the release of growth hormone; however, estrogen levels naturally decline with age.  Ipamorelin injections may help supplement low growth hormone levels and alleviate menopausal symptoms. 

5 Amino 1 MQ plays an instrumental role in the metabolism of fat. This compound is recognized for its ability to block an enzyme known as NNMT, associated with obesity and the storage of fat.

5 Amino 1 MQ enhances the presence of another crucial molecule named NAD+. NAD+ is indispensable in energy creation within your cells, particularly during physical activity. Increased NAD+ levels in the body results in more effective fat incineration.

Here’s what 5 Amino-1MQ offers:   

• Promotes Weight Loss - By inhibiting the enzyme NNMT, 5 Amino 1 MQ can help reduce the amount of fat stored in the body, leading to weight loss.

• Enhances Energy Production - 5 Amino 1 MQ increases the availability of NAD+, a crucial molecule in cellular energy production. This could potentially lead to increased energy levels, especially during physical activities.

• Improves Metabolic Function - 5 Amino 1 MQ helps speed up metabolism, which is crucial for burning calories and losing weight. A faster metabolism can also increase energy levels and improve overall health.

• Reduces Fat Accumulation - By inhibiting the NNMT enzyme associated with fat storage, 5 Amino 1 MQ can help to prevent new fat accumulation in the body.

• Suppresses Appetite - Some research suggests that 5 Amino 1 MQ may also help to suppress appetite, further aiding in weight management.

• Potential Therapeutic Effects -There’s ongoing research into the therapeutic potential of 5 Amino 1 MQ for a variety of health conditions, including certain types of cancer and neurological disorders.